Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

TSE:DOSE

Rapid Dose Therapeutics Corp

(CNQX:DOSE)

Select Model
Rating:42Neutral
Price Target:CAD 0.11â–²(0.95% Upside)
Action:reiterated
Date:10/14/26

The overall score is heavily constrained by a fragile financial position, marked by negative equity and high debt, despite recent operational cash flow improvements. Technical trends are bearish with the stock trading below key moving averages, and the negative P/E ratio underscores the lack of current profitability. The modest cash flow turnaround is a positive signal but is not yet sufficient to offset the significant balance sheet risks.

Positive Factors
Proprietary delivery platformThe proprietary QuickStrip platform provides a differentiated drug-delivery format with potential convenience advantages for users. Its applicability across pharmaceuticals, nutraceuticals, and other active compounds could support multiple commercialization opportunities over the next several quarters.
Negative Factors
Shrinking revenue and weak profitabilityDeclining revenue combined with negative gross profit indicates that the current commercial base is not yet producing healthy underlying economics. Persistent operating losses and net losses larger than revenue could constrain reinvestment and make sustained growth difficult.

Rapid Dose Therapeutics Corp (DOSE) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%TSE:DOSE-36.36%EWC+21.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
CAD 14.33M
Dividend Yield
―
Average Volume (3M)
35.68K
Price to Earnings (P/E)
-4.4
Beta (1Y)
0.51
Revenue Growth
4.30%
EPS Growth
38.28%
Country
Canada
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship p...

How the Company Makes Money

Rapid Dose Therapeutics primarily makes money by monetizing its QuickStrip drug-delivery technology through commercial and strategic arrangements rather than by operating as a large, fully integrated drug manufacturer. Key revenue sources may include...

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Financial performance is mixed. Narrowing net losses and a shift to positive operating cash flow are encouraging signs of operational improvement. However, the balance sheet is severely stressed with negative equity and high leverage, while TTM revenue has declined and gross margins turned negative. The overall financial health remains fragile.

Income Statement

25Negative

Balance Sheet

10Very Negative

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMMay 2026May 2025May 2024Nov 2022Feb 2021
Income Statement
Total Revenue2.77M2.77M2.09M1.02M1.75M755.20K
Gross Profit280.86K-956.89K1.18M563.41K1.34M699.85K
EBITDA-1.66M-1.66M-3.93M-3.02M-7.59M-987.00K
Net Income-3.39M-3.39M-5.40M-4.31M-8.49M-1.80M
Balance Sheet
Total Assets3.28M3.28M1.63M1.89M3.07M3.83M
Cash, Cash Equivalents and Short-Term Investments11.55K11.55K20.72K161.06K34.44K70.26K
Total Debt5.32M5.32M2.61M2.45M1.43M2.06M
Total Liabilities10.46M10.46M6.84M5.04M2.82M5.41M
Stockholders Equity-7.18M-7.18M-5.21M-3.16M251.56K-1.58M
Cash Flow
Free Cash Flow-313.43K-271.29K-1.15M-2.29M-3.04M-1.63M
Operating Cash Flow-311.63K-270.39K-1.15M-2.29M-3.00M-1.62M
Investing Cash Flow-899-899-5,74001.85M-9,124
Financing Cash Flow262.13K262.13K1.01M2.43M1.13M1.65M

Rapid Dose Therapeutics Corp Technical Analysis

Technical Analysis SentimentNegative
Last Price0.10

Price Trends

50DMA0.10Negative
100DMA0.10Negative
200DMA0.11Negative

Market Momentum

MACD-0.00Negative
RSI49.74Neutral
STOCH88.89Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.10 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.74 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:DOSE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:BLABTSE:BLAB52NeutralCAD 11.36M0.76101.66%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:DOSETSE:DOSE42NeutralCAD 14.33M-4.4146.54%―4.30%38.28%
TSE:TELITSE:TELI41NeutralCAD 24.65M5.71114.66%―94.58%―
TSE:BCTTSE:BCT39UnderperformCAD 37.55M-0.33-170.70%――87.90%
TSE:HEMTSE:HEM39UnderperformCAD 11.63M-2.4392.37%――16.04%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%TSE:DOSETSE:BCTTSE:HEMTSE:BLABTSE:TELIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
TSE:DOSE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:DOSERapid Dose Therapeutics Corp0.10-0.06-34.38%
TSE:BCTBriaCell Therapeutics4.30-9.65-69.18%
TSE:HEMHemostemix Inc0.06-0.04-42.11%
TSE:BLABBritannia Life Sciences Inc0.07-0.03-33.33%
TSE:TELITelescope Innovations Corp0.30-0.09-21.79%

Rapid Dose Therapeutics Corp Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Rapid Dose Converts Interest and Director Fees to Equity to Strengthen Balance Sheet

Positive
Oct 5, 2026

Rapid Dose Therapeutics Corp. will issue 1,092,821 common shares to holders of its amended and restated secured convertible notes as payment for approximately $142,000 in quarterly accrued interest, based on a deemed price of $0.13 per share. This mo...

Business Operations and StrategyProduct-Related Announcements

Rapid Dose Therapeutics Secures Second Patent for QuickStrip Nicotine Oral Film

Positive
Aug 26, 2026

Rapid Dose Therapeutics and Aavishkar Oral Strips have secured a second Indian patent for their QuickStrip Nicotine oral-film technology, this time covering a monolayer formulation and related manufacturing processes. The new 20-year patent complemen...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 14, 2026